Literature DB >> 8027238

c-myc, c-fos, and c-myb gene expression in human pituitary adenomas.

M Woloschak1, J L Roberts, K Post.   

Abstract

The possible roles of certain oncogenes in the development of pituitary tumors has not been investigated. We have examined the expression of c-myc, c-fos, and c-myb in a number of human pituitary tumors by ribonuclease protection assays, as these oncogenes have been implicated to have roles in the pathogenesis of other human tumors (12, 13, 15, 16). In several tumors examined (9 of 30) c-myc was expressed at levels 4-9 times greater than the level detected in normal postmortem pituitary. Although a larger percentage of negative immunohistochemical-staining tumors overexpressed c-myc, c-myc over-expression was not limited to this group of tumors. c-Fos was overexpressed in 1 of 30 tumors examined at a level 5.8-fold higher than that detected in normal postmortem pituitary. This tumor stained positive for ACTH by immunohistochemistry and was considered highly aggressive, demonstrating invasion beyond the sella turcica; however, when other ACTH-staining and invasive pituitary tumors were examined, no abnormality in the expression of c-fos was detected. In 30 tumors, c-myb was expressed at approximately the same level as that detected in normal postmortem pituitary. We conclude that c-myc is overexpressed in a subgroup of pituitary tumors and that this overexpression occurs broadly among the different groups of immunohistochemical-staining tumors. c-Fos overexpression appears to be much less common in pituitary tumors and does not necessarily correlate with the ability of the tumor to become invasive. c-Myb does not appear to have a role in the pathogenesis of pituitary tumors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8027238     DOI: 10.1210/jcem.79.1.8027238

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  14 in total

Review 1.  Pathogenesis of prolactinomas.

Authors:  Anna Spada; Giovanna Mantovani; Andrea Lania
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

Review 2.  Isolation and characterization of novel pituitary tumor related genes: a cDNA representational difference approach.

Authors:  Xun Zhang; Yunli Zhou; Anne Klibanski
Journal:  Mol Cell Endocrinol       Date:  2010-03-06       Impact factor: 4.102

Review 3.  Genetic basis of pituitary adenoma invasiveness: a review.

Authors:  A Suhardja; K Kovacs; J Rutka
Journal:  J Neurooncol       Date:  2001-05       Impact factor: 4.130

Review 4.  Role of transcription factors in the pathogenesis of pituitary adenomas: a review.

Authors:  A Suhardja; K Kovacs; J Rutka
Journal:  J Neurooncol       Date:  2001-12       Impact factor: 4.130

Review 5.  Genesis of pituitary adenomas: state of the art.

Authors:  G Faglia; A Spada
Journal:  J Neurooncol       Date:  2001-09       Impact factor: 4.130

6.  Loss of heterozygosity of the MEN1 gene in a large series of TSH-secreting pituitary adenomas.

Authors:  C Asteria; M Anagni; L Persani; P Beck-Peccoz
Journal:  J Endocrinol Invest       Date:  2001-11       Impact factor: 4.256

7.  Expression of bcl-2 oncoprotein in pituitary tumours: comparison with c-myc.

Authors:  D G Wang; C F Johnston; A B Atkinson; A P Heaney; M Mirakhur; K D Buchanan
Journal:  J Clin Pathol       Date:  1996-10       Impact factor: 3.411

Review 8.  Mechanisms for pituitary tumorigenesis: the plastic pituitary.

Authors:  Shlomo Melmed
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

9.  Immunolocalization of Pit-1 in gonadotroph nuclei is indicative of the transdifferentiation of gonadotroph to lactotroph cells in prolactinomas induced by estrogen.

Authors:  Jorge Humberto Mukdsi; Ana Lucía De Paul; Sonia Muñoz; Agustín Aoki; Alicia Inés Torres
Journal:  Histochem Cell Biol       Date:  2004-06-09       Impact factor: 4.304

10.  Pituitary Carcinomas.

Authors:  Wolfgang Saeger; Dorothee Lubke
Journal:  Endocr Pathol       Date:  1996       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.